Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
9 evidence topics · 7 sources
miR-124 expression in rectal biopsies and blood: phase 2b induction trial
“The number of miR-124 copies was determined by ddPCR, at baseline and after 8 weeks of treatment, in rectal biopsies and blood samples from patients who received ABX464 (25, 50, or 100 mg) or placebo during a phase 2b trial (10) (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 8, the number of miR-124 copies was significantly higher in the treatment groups than in the placebo group (the mean number of copies/cell: placebo, 746; ABX464 [25, 50, and 100 mg], 8,345, 8,347, and 9,171, respectively; Figure 4b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 8, the number of miR-124 copies was significantly higher in each treatment group than in the placebo group (the mean number of copies/cell: placebo, 28.93; ABX464 [25, 50, and 100 mg], 4,598, 8,517, and 13,753, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 576 rectal biopsies from 139 patients and 1,104 blood samples from 229 patients who received ABX464 (25, 50, or 100 mg) or placebo were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum cytokines: phase 2b induction trial
“For the cell and cytokine (IL1b, IL4, IL6, IL10, IL23, IFNγ, CCL2, TNF-α, and IL17a) analysis in serum samples from patients who received either ABX464 during the phase 2b trial (10), significant changes vs placebo were seen only for IL17a, at all doses, with no dose-dependent effect (Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, a reduction in Th17 population and IL17a expression was observed in serum samples, but it was not dose-dependent (see Discussion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
miR-124 expression and serum IL-17A and IL-6: ABTECT induction trials
miR-124 expression through 96 weeks: phase 2b open-label maintenance study
“Treatment with obefazimod 50 mg significantly enhanced the expression of miR-124 in blood and rectal tissue at weeks 48 and 96 (P < .001 vs. baseline) (Figure 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enhanced expression of miR-124 was observed in both rectal tissue and blood of patients receiving obefazimod 50 mg during the OLM study, including those previously receiving placebo during the induction study (Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
miR-124 induction and Th17 cells in human immune cells: in vitro studies
“In this analysis, ABX464 treatment resulted in significant upregulation of miR-124 levels; specifically, the increases in miR-124 levels were 9-fold in PBMCs (Figure 1a), 7-fold in purified CD4+ cells (Figure 1b), and 9-fold in macrophages (Figure 1c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464 treatment did not change Th1+ cells but significantly decreased Th17 cells (−39.1%, P = 0.0002) or Th17+ like Th1+ (Figure 2b), confirmed by significant decreases (−50.8%, P < 0.0001) in IL17a-secreting cells (Figure 2c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dextran sodium sulfate colitis in mice
“Treatment with ABX464 significantly reversed the increases in several proinflammatory cytokines induced by DSS (GM-CSF, IL10, IL34, TPO, LIF, CXCL12, IL6, and CCL2) and maintained their levels close to those of healthy H2O-treated mice (Figure 7a–c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464 treatment reversed the DSS-induced upregulation of IL17a-secreting cells (−54.2%, P < 0.0001 vs untreated DSS mice) and maintained them at a level equivalent to that in healthy H2O-treated mice (P > 0.9999) (Figure 8a), which further support the effect of ABX464 on adaptive immunity through the reduction of the Th17-positive and CD4-positive subsets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464 treatment strongly attenuated DSS-induced colitis in mice and produced a long-term protection against prolonged DSS-exposure after drug cessation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, RNA profiling analysis revealed the capacity of ABX464 to induce the expression of IL-22, a cytokine involved in colitis tissue repair, both in DSS-treated mice and in LPS-stimulated bone marrow-derived macrophages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, anti-IL-22 antibodies significantly reduced the protective effect of ABX464 on colitis in DSS-treated mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote